American College of Cardiology

APRIL 7, 2024

The goal of the DanGer Shock trial was to compare the safety and efficacy of Impella CP on top of standard care compared with standard care alone among patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock.

Cardiogenic Shock 74

Cardiogenic Shock Myocardial Infarction STEMI Article 74

American College of Cardiology

JUNE 25, 2024

Cardiogenic shock is a common complication in patients who present with acute myocardial infarction (AMI) and is the leading cause of death in this population. Even with immediate revascularization, death rates remain high.

Cardiogenic Shock 58

Cardiogenic Shock Myocardial Infarction Article 58

European Journal of Heart Failure

FEBRUARY 23, 2024

Cardiogenic shock is a primary cardiac disorder that results in both clinical and biochemical evidence of tissue hypoperfusion and can lead to multi-organ failure and death depending on its severity. Despite some advances in cardiogenic shock management, this clinical syndrome is still burdened by an extremely high mortality.

Cardiogenic Shock 75

Cardiogenic Shock Myocardial Infarction Article 75

American College of Cardiology

SEPTEMBER 13, 2024

The goal of the ECLS-SHOCK trial was to evaluate extracorporeal life support (ECLS) compared with control among patients with acute myocardial infarction (MI) and cardiogenic shock.

Cardiogenic Shock 49

Cardiogenic Shock Myocardial Infarction Article 49

Journal of Cardiothoracic Surgery

FEBRUARY 19, 2025

Patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) face high mortality rates. Extracorporeal Membrane Oxygenation (ECMO) therapy offers critical support in these cases, yet i.

Cardiogenic Shock 52

Cardiogenic Shock Myocardial Infarction Risk Factors Research 52

Frontiers in Cardiovascular Medicine

OCTOBER 13, 2024

BackgroundIn the ICU, patients with acute myocardial infarction and cardiogenic shock (AMI-CS) often face high mortality rates, making timely and precise mortality risk prediction crucial for clinical decision-making.

Cardiogenic Shock 52

Cardiogenic Shock Myocardial Infarction ICU 52

Nature Reviews - Cardiology

APRIL 22, 2024

Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01035-9 Data from the DanGer Shock trial demonstrate that implantation of a microaxial flow pump in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock increases the survival rate compared with standard care alone.

Cardiogenic Shock 52

Cardiogenic Shock STEMI Myocardial Infarction 52

European Journal of Heart Failure

JANUARY 17, 2025

Predictors of weaning failure from veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in patients with cardiogenic shock. The cause of CS was acute myocardial infarction in 438 (63.9%) patients, and 431 (62.9%) patients presented with cardiac arrest. RRT, renal replacement therapy. interquartile range 4.112.7]

Cardiogenic Shock 66

Cardiogenic Shock Cardiac Arrest Myocardial Infarction Hospital 66

Frontiers in Cardiovascular Medicine

JANUARY 3, 2024

Although the contemporary shock stages classification provided a standardized shock severity assessment, individual agents or management strategy has not yet been studied in the context of each shock stage. The pre-shock state may comprise a wide range of presentations.

Cardiogenic Shock 90

Cardiogenic Shock Myocardial Infarction Heart Failure Outcomes 90

Frontiers in Cardiovascular Medicine

JANUARY 2, 2024

Background Data are lacking on the effects of the alternation of P2Y12 receptor antagonists (P2Y12) on bleeding and outcome in patients with myocardial infarction (MI) with cardiogenic shock (CS).

Cardiogenic Shock 59

Cardiogenic Shock Myocardial Infarction Outcomes 59

Frontiers in Cardiovascular Medicine

FEBRUARY 24, 2025

This case report describes a unique instance of a patient developing AEF following AF ablation, accompanied by ischemic stroke and myocardial infarction. Upon admission, physical examination and laboratory tests revealed vital signs within abnormal ranges and indicators suggesting inflammation and potential myocardial injury.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Cardiogenic Shock Myocardial Infarction 52

European Journal of Heart Failure

DECEMBER 13, 2023

Impella and venoarterial extracorporeal membrane oxygenation (VA-ECMO) in patients with acute myocardial infarction-related cardiogenic shock (AMICS). Methods and results This nationwide observational cohort study describes all AMICS patients treated with Impella (ABIOMED, Danvers, MA, USA) and/or VA-ECMO in 2020–2021.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Cardiac Arrest Hospital 40

The New England Journal of Medicine

APRIL 6, 2024

Acute myocardial infarction–related cardiogenic shock (AMI-CS) is characterized by systemic hypoperfusion due to cardiomyocyte necrosis and ventricular dysfunction.1 2 Prompt reperfusion.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Hospital 40

Circulation: Cardiovascular Interventions

JANUARY 31, 2024

BACKGROUND:In patients with ST-segment–elevation myocardial infarction complicated by cardiogenic shock, primary percutaneous coronary intervention (pPCI) is the preferred revascularization option. pharmacoinvasive and 46.2% pharmacoinvasive and 46.2% The incidence of the primary safety outcome was 10.1% 1.09];P=0.08).CONCLUSIONS:In

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Cardiac Arrest Cardiovascular Interventions 40

Journal of the American Heart Association

NOVEMBER 28, 2023

BackgroundAcute myocardial infarction complicated by cardiogenic shock (AMI‐CS) is associated with significant morbidity and mortality. Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Blood Pressure Cardiac Arrest 40

Open Heart

DECEMBER 7, 2023

Introduction Cardiogenic shock (CS) complicates 5%–15% of cases of acute myocardial infarction (AMI) with inpatient mortality greater than 40%. The implementation of standardised protocols may improve clinical outcomes in patients with AMI-CS.

Cardiogenic Shock 52

Cardiogenic Shock Myocardial Infarction STEMI Heart attacks 52

Dr. S. Venkatesan MD

DECEMBER 29, 2023

Cardiogenic shock (CS)is the most feared event following STEMI. Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes. The incidence is up to 5 to 10% with a mortality rate of around 50-60%. Still, we are finding it hard to bring this down below 50 %. Reference 1.Martínez J Clin Med.

Cardiogenic Shock 52

Cardiogenic Shock STEMI Myocardial Infarction Document 52

The American Journal of Cardiology

JULY 24, 2024

Publication date: Available online 23 July 2024 Source: The American Journal of Cardiology Author(s): Kahtan Fadah, Helayna Abraham, Subhash Banerjee, Debabrata Mukherjee

Cardiogenic Shock 52

Cardiogenic Shock Myocardial Infarction 52

JAMA Cardiology

OCTOBER 26, 2024

In a seminal case series published in 1967, Killip and Kimball reported 81% in-hospital mortality for patients presenting with acute myocardial infarction complicated by cardiogenic shock (AMI-CS).

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Heart Failure Hospital 40

Journal of the American Heart Association

JANUARY 31, 2024

BackgroundThe Society for Cardiovascular Angiography and Interventions proposed a staging system (A–E) to predict prognosis in cardiogenic shock. Patients enrolled in the RECOVER III study were assigned a baseline Society for Cardiovascular Angiography and Interventions shock stage. P<0.001).ConclusionsIn

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Outcomes 40

Frontiers in Cardiovascular Medicine

JULY 22, 2024

IntroductionIn developing countries, there is a notable scarcity of real-world data on adherence to optimal medical therapy (OMT) and its correlation with major cardiovascular adverse events (MACEs) after ST-elevation myocardial infarction (STEMI). Patients were followed up for 4.5 ResultsWe included 349 patients with a mean age of 58.08

Myocardial Infarction 59

Myocardial Infarction Risk Factors Cardiogenic Shock STEMI 59

Journal of the American Heart Association

FEBRUARY 16, 2024

BackgroundClinical outcome of ischemic cardiogenic shock (CS) requiring extracorporeal membrane oxygenation is highly variable, necessitating appropriate assessment of prognosis. However, a systemic predictive model estimating the mortality of refractory ischemic CS is lacking.

Cardiogenic Shock 45

Cardiogenic Shock Hospital Myocardial Infarction Kidney Disease 45

Journal of the American Heart Association

FEBRUARY 26, 2025

BackgroundCardiogenic shock carries high mortality. male, 67% acute myocardial infarction, 33% acute decompensated heart failure), 45 (41.3%), 33 (30.3%), and 31 (28.4%) were in SCAI Shock Stages C, D, and E, respectively. A suggestive trend of improving 30day survival was observed (56.8%, 63.9%, and 72.2%

Cardiogenic Shock 40

Cardiogenic Shock Best Practices Myocardial Infarction Pulmonary 40

European Journal of Heart Failure

DECEMBER 12, 2023

Abstract Objectives This study aimed to assess the impact of anemia and iron deficiency (ID) on clinical outcome in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI).

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Outcomes Catheterization Laboratory 40

Cardiovascular Diabetology

SEPTEMBER 10, 2024

Triglyceride-glucose (TyG) index, a dependable indicator of insulin resistance, has been identified as a valid marker regarding multiple cardiovascular diseases. Nevertheless, the correlation of TyG index with.

Cardiogenic Shock 59

Cardiogenic Shock Myocardial Infarction Cardiovascular Disease Research 59

European Journal of Heart Failure

JANUARY 14, 2025

The International Registry of MitraClip in Acute Mitral Regurgitation following Acute Myocardial Infarction (IREMMI). Methods and results The International Registry of MitraClip in Acute Mitral Regurgitation following Acute Myocardial Infarction (IREMMI) includes 187 patients with severe MR post-MI managed with TEER.

Myocardial Infarction 40

Myocardial Infarction Bicuspid/Mitral Cardiogenic Shock Risk Factors 40

Frontiers in Cardiovascular Medicine

MARCH 10, 2024

Background Hyperglycemia, characterized by elevated blood glucose levels, is frequently observed in patients with acute coronary syndrome, including ST-elevation myocardial infarction (STEMI). 1.77), cardiogenic shock (pooled RR 3.68, 95% CI 2.65–5.11), 2.17), heart failure (pooled RR 1.56, 95% CI: 1.37–1.77),

Myocardial Infarction 59

Myocardial Infarction Cardiogenic Shock Article Outcomes 59

The American Journal of Cardiology

APRIL 6, 2024

Publication date: Available online 5 April 2024 Source: The American Journal of Cardiology Author(s): Amit Saha, Shuang Li, James A. de Lemos, Ambarish Pandey, Deepak L. Bhatt, Gregg C. Fonarow, Brahmajee K. Nallamothu, Tracy Y.MHS WangMSc, Ann Marie Navar, Eric Peterson, Roland A. Matsouaka, Anthony A. Bavry, Sandeep R. Das, Justin L.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Hospital 40

Dr. Smith's ECG Blog

SEPTEMBER 5, 2024

This is a value typical for a large subacute MI, n ormal value 48 hours after myocardial infarction is associated with Post-Infarction Regional Pericarditis ( PIRP ). PIRP is strongly associated with myocardial rupture. The VSR is what is causing the cardiogenic shock! Heart rate was in the 80s. Hammill SC.

Cardiogenic Shock 110

Cardiogenic Shock Chest Pain Pericarditis Myocardial Infarction 110

American College of Cardiology

SEPTEMBER 9, 2024

What is the effect of early routine active percutaneous mechanical circulatory support (MCS) versus control treatment on 6-month all-cause mortality in patients with acute myocardial infarction-related cardiogenic shock (AMICS)?

Cardiogenic Shock 49

Cardiogenic Shock Myocardial Infarction Article 49

NEJM Journal Watch - Cardiology

APRIL 8, 2024

Placement of a microaxial flow pump reduced mortality in patients with this dire complication of acute myocardial infarction.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction 40

Clinical Trial Results

SEPTEMBER 2, 2024

Disclosures: TBD

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction 40

The American Journal of Cardiology

OCTOBER 11, 2024

Publication date: Available online 11 October 2024 Source: The American Journal of Cardiology Author(s): Carlos Diaz-Arocutipa, Norma Nicole Gamarra-Valverde, Rafael Salguero, Roberto Martín-Asenjo, Lourdes Vicent

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Outcomes 40

Circulation: Cardiovascular Interventions

JANUARY 31, 2024

Circulation: Cardiovascular Interventions, Ahead of Print.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Cardiovascular Interventions Circulation 40

DAIC

APRIL 8, 2024

milla1cf Mon, 04/08/2024 - 18:07 April 8, 2024 — Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly increased the rate of survival at six months among people suffering cardiogenic shock, according to a study presented at the American College of Cardiology ’s Annual Scientific Session.

Heart attacks 52

Heart attacks Heart Attack Cardiogenic Shock Catheterization Laboratory 52

DAIC

MARCH 21, 2024

Impella Left Sided Blood Pumps also are used when there is ongoing cardiogenic shock that occurs less than 48 hours after a severe heart attack (acute myocardial infarction), open-heart surgery, or when the heart is not functioning well due to a condition called cardiomyopathy.

Cardiogenic Shock 104

Cardiogenic Shock Open-Heart Surgery Myocardial Infarction Heart attacks 104

Open Heart

JUNE 5, 2024

vs 3.9%, p<0.001) and ST-elevation myocardial infarction (59.1% vs 50.8%, p<0.001) and were more likely to experience postprocedural cardiogenic shock (4.5% At 30 days, mortality, myocardial infarction, revascularisation and major adverse cardiac and cerebrovascular events did not differ between the groups.

Cardiogenic Shock 52

Cardiogenic Shock Myocardial Infarction Outcomes Coronary Artery Disease 52